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Monoclonal antibodies find broad application as therapy for various types of cancer by 
employing multiple mechanisms of action against tumors. Manipulating the Fc-mediated 
functions of antibodies that engage immune effector cells, such as NK cells, represents a 
strategy to influence effector cell activation and to enhance antibody potency and poten-
tially efficacy. We developed a novel approach to generate and ascertain the functional 
attributes of Fc mutant monoclonal antibodies. This entailed coupling single expression 
vector (pVitro1) antibody cloning, using polymerase incomplete primer extension (PIPE) 
polymerase chain reaction, together with simultaneous Fc region point mutagenesis 
and high yield transient expression in human mammalian cells. Employing this, we 
engineered wild type, low (N297Q, NQ), and high (S239D/I332E, DE) FcR-binding Fc 
mutant monoclonal antibody panels recognizing two cancer antigens, HER2/neu and 
chondroitin sulfate proteoglycan 4. Antibodies were generated with universal mutagenic 
primers applicable to any IgG1 pVitro1 constructs, with high mutagenesis and transfec-
tion efficiency, in small culture volumes, at high yields and within 12 days from design to 
purified material. Antibody variants conserved their Fab-mediated recognition of target 
antigens and their direct anti-proliferative effects against cancer cells. Fc mutations 
had a significant impact on antibody interactions with Fc receptors (FcRs) on human 
NK cells, and consequently on the potency of NK cell activation, quantified by immune 
complex-mediated calcium mobilization and by antibody-dependent cellular cytotoxicity 
(ADCC) of tumor cells. This strategy for manipulation and testing of Fc region engage-
ment with cognate FcRs can facilitate the design of antibodies with defined effector 
functions and potentially enhanced efficacy against tumor cells.
Keywords: antibodies, cancer immunotherapy, mutants, cloning, expression, aDcc, her2, chondroitin sulfate 
proteoglycan 4
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inTrODUcTiOn
Monoclonal antibodies for cancer therapy engender a range 
of anti-tumor functions. These may be defined by Fab region 
recognition of target antigen epitopes and by engagement of 
the Fc region with cognate Fc receptors (FcR) on a variety of 
effector cell subsets. Anti-tumor functions can include direct 
tumor cell killing through Fab-mediated antagonistic activ-
ity (1–6), or modulating the behavior of cytotoxic T  cells by 
checkpoint blockade (7, 8). Furthermore, Fc-mediated effects 
such as complement-dependent cytotoxicity (CDC) (6, 9, 10), 
antibody-dependent cellular cytotoxicity (ADCC) (5, 6, 11, 12) 
and phagocytosis (ADCP) (13) constitute important functions 
of a large proportion of clinically used antibodies in oncology. 
As many antibodies can exert multimodal anti-tumor activities 
influenced by both Fab- and Fc-mediated effects (6, 14), engi-
neering antibodies with defined attributes and delineating their 
mechanisms of action is important for the generation of effective 
therapeutic agents.
The Fc portion of the antibody and the nature and affinity of 
its interactions with FcRs are critical in determining antibody 
serum and tissue half-life, bio-distribution (15), recruitment, 
and activation of immune effector cells such as NK  cells and 
macrophages against specific target cells (16). Even though 
monoclonal antibodies are potent anti-cancer therapeutics, their 
potency in restricting disease progression may be limited by 
low affinity for activating FcRs, competition with endogenous 
serum antibodies, low half-life in tissues and interactions with 
the inhibitory Fcγ receptor, FcγRIIB, which restricts effector 
cell functions (17, 18). On the other hand, agonistic antibodies 
specific for the TNFR family molecules have been reported to 
be significantly more efficacious if they have higher affinity for 
the inhibitory receptor FcγRIIB and lower affinity for activating 
FcRs (19, 20). This further highlights the crucial importance of 
assessing the contributions of the Fc region in different antibody 
immunotherapy approaches for cancer and the unmet need for 
novel Fc-engineered antibody variants to serve the purposes 
of specific strategies. Protein engineering methods utilizing 
structural bioinformatics and computational design have identi-
fied amino acid residues that can play key roles in enhancing 
antibody FcR-binding and Fc-mediated functional capabilities 
(21). Alternatively, abrogation of antibody binding to FcRs and 
abolition of Fc-mediated effector functions could be a useful 
approach for the design of antibodies with direct agonistic or 
antagonistic activities where effector cell engagement may not 
be desirable (22–25). Developing a strategy to easily manipulate 
antibody Fc regions can help to dissect the mechanisms of action 
of anti-cancer antibodies, allowing analysis of Fab-mediated 
functions in the presence or absence of Fc-mediated activities. 
Such approaches could find a broad applicability in therapeutic 
antibody engineering and translation (26–28).
In vitro and in  vivo potency and mechanistic evaluations 
of engineered antibodies and their downstream applications 
in cancer research are heavily dependent on the availability of 
sufficient quantities of high quality functional material gener-
ated from expression systems such as human embryonic kidney 
(HEK293), Chinese hamster ovary (CHO), and mouse myeloma 
(SP2/0, NS0) cells (29–31), mostly utilizing variable regions 
derived from hybridoma (32, 33) or phage display technolo-
gies (34). Current approaches largely rely on the generation of 
stable expressing cell lines, and do not include efficient built-in 
tools for sequence engineering and mutagenesis, which may be 
lengthy and labor-intensive (35).
We previously reported the design and implementation of 
a single dual expression vector system combined with efficient 
insertion of any antibody variable and constant regions through 
polymerase incomplete primer extension (PIPE) cloning. 
We showed that this can facilitate antibody production by human 
embryonic kidney (HEK293F) cells (36, 37). In this study, by 
employing a novel cloning approach based on PIPE combined 
with simultaneous point mutagenesis, we generate monoclonal 
antibodies specific for tumor-associated antigens with modified 
Fc domains designed to alter interactions with immune effec-
tor cells. Most well established mutagenesis cloning methods 
require a two round PCR method or cannot be applied to large 
plasmids without increasing the risk of random amplifica-
tion error (37–40). Our study represents an improvement of 
traditional PCR mutagenesis methods by offering efficient 
mutagenesis (requiring one round of PCR only), combined 
with enzyme-free cloning for the generation of large expression-
ready constructs (over 8,000 kb). We also designed this system 
to allow generation of different versions of the same antibody 
construct. This could find wide applicability for functional and 
translational studies and could be applied to any IgG1 antibody 
due to the universal nature of the mutagenesis approach we are 
employing. To our knowledge, this is the first antibody produc-
tion platform that combines generation and functional valida-
tion of high yields of specific Fc mutant antibodies. With this 
strategy, we aim to design agents with defined effector functions 
in a substantially shorter timeframe, employing small culture 
volumes and at significantly higher yields.
MaTerials anD MeThODs
isolation of human immune cells
Peripheral blood was obtained through the UK National 
Health System (NHS) Blood and Transplant system from 
anonymous donor leukocyte cones. NK  cells were isolated 
using RosetteSep™ Human NK Cell Enrichment Cocktail 
(STEMCELL™ Technologies), according to the manufacturer’s 
instructions.
cell culture
All tumor cell lines were sustained at 37°C in a humidified 
atmosphere in 5% CO2, unless otherwise specified. Cell culture 
medium was supplemented with 10% fetal calf serum (FCS, 
Thermo Fischer Scientific), unless otherwise specified. Adherent 
cells were detached using 0.25% Trypsin-EDTA except for 
cancer cell lines expressing the trypsin sensitive antigen chon-
droitin sulfate proteoglycan 4 (CSPG4), which were detached 
using 5 mM EDTA solution in phosphate buffered saline (PBS). 
The cell lines BT-474 (invasive ductal carcinoma, primary 
site derived), SK-BR-3 (invasive ductal carcinoma, metastasis 
Table 1 | PCR primers for generation of anti-HER2 and anti–CSPG4 Fc mutant 
antibodies.
Primer 
name
sequence 5′→3′ Mutation amplified 
fragment
F-DE-1 CAGCACCTGAACTCCTGGGGGG 
ACCGgacGTCTTCCTCTTCCCCC
S239D DE F1
R-DE-1 GGGGCTGCCCTTTGGCTTTGGAGATG 
GTTTTCTCTTcGGGGGCTGG
I332E DE F1
F-DE-2 CCAGCCCCCgaaGAGAAAACCATC 
TCCAAAGCCAAAGGGCAGCCCC
I332E DE F2
R-pVitro-
1-Kappa
ACCGCGGCTAGCTGGAACCC 
AGAGCAGCAGAAACCCAATG
– DE F2
F-pVitro-
VL-Univ
CATTGGGTTTCTGCTGCTCTG 
GGTTCCAGCTAGCCGCGGT
– DE F3
R-DE-3/
R-NQ-3
GGGGGAAGAGGAAGACGTCCGG 
TCCCCCCAGGAGTTCAGGTGCTG
– DE F3; NQ F3
F-DE-4/ 
F-NQ-4
GTTGCTTTGATTACAACACTGGA 
GAGAAATGCAGCATGTTGCTGATT
–- DE F4; NQ F4
R-DE-4 GGGGGAAGAGGAAGACgTcCG 
GTCCCCCCAGGAGTTCAGGTGCTG
S239D DE F4
F-NQ-1 cagAGCACGTACCGGGTGGT
CAGCGTCCTCACCGTCCTGCACCAG
N297Q NQ F1
R-NQ-1 TGATCTACCCGCGCTCAGCCC 
TGGGCGCATGCTCCTCGCGCTGTC
– NQ F1
F-NQ-2 CGAGGAGCATGCGCCCAGGG 
CTGAGCGCGGGTAGATCAGAGCACA
– NQ F2
R-NQ-2 TACAAAGTGTTACCCCTCTAG 
ACCTGGAAAGACCAGGCGGAGTTT
– NQ F2
F-NQ-3 GCCTGGTCTTTCCAGGTCTAG 
AGGGGTAACACTTTGTACTGCGTT
– NQ F3
R-NQ-4 AGGACGGTGAGGACGCTGACCACC 
CGGTACGTGCTcTgGTACTGC
N297Q NQ F4
Underlined nucleotides depict mutated codons; sequences in red font indicate mutated 
nucleotides.
Table 2 | PIPE PCR fragments with accompanying specific PCR extension 
times for fragment amplification.
Fragment approximate size (bp) extension time (s)
NQ F1 ~2,000 28
NQ F2 ~2,000 28
NQ F3 ~2,000 28
NQ F4 ~2,600 35
DE F1 ~350 5
DE F2 ~3,150 42
DE F3 ~2,800 35
DE F4 ~2,400 35
3
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origin) MDA-MB-231 (invasive ductal carcinoma, metastasis 
origin), and Hs 578T (breast carcinoma, primary site derived) 
were purchased from the American Tissue Culture Collection 
(ATCC) and cultured in DMEM GlutaMAX™ (Thermo Fischer 
Scientific). The cell lines HCC1954 (invasive ductal carcinoma, 
primary site derived), MDA-MB-231 HTB-26 (human breast 
adenocarcinoma, metastasis origin), ZR-75-30 (invasive ductal 
carcinoma, metastasis origin) and BT-549 (invasive ductal car-
cinoma, lymph node metastasis origin) were purchased from 
ATCC and cultured in RPMI GlutaMAX™ (Thermo Fischer 
Scientific). MDA-MB-231-CSPG4+++ cells were generated in-
house by knocking in the coding sequence of the full-length 
tumor-associated antigen CSPG4 (GenBank accession number 
BC172576) and cells were cultured as the wild type (WT) cells. 
Expi293F cells (Thermo Fischer Scientific) were grown on a 
Stuart orbital shaker (model SSL1) (41), at 125 rpm in 8% CO2 
in serum-free Expi293 expression medium (Thermo Fischer 
Scientific).
generation of Fc Mutant antibodies
The amino acid sequences of the trastuzumab heavy and light 
variable regions were obtained from the DrugBank database 
(www.drugbank.ca), translated in nucleotide sequences and 
manually codon optimized for a human expression host. 
Optimized sequences were synthesized using GeneArt Gene 
Synthesis (Thermo Fischer Scientific). The variable region 
fragments of trastuzumab were then cloned into pVitro1-
hygro-mcs vector as previously described (36). PIPE PCR was 
then performed using the ready cloned WT antibody pVitro1 
constructs as a template and mutagenic PIPE primers to 
generate four linear fragments of the construct with 5′ PIPE 
overhangs (“sticky ends” for PIPE cloning) and the desired 
point mutations (Table 1). The PCR reagents are listed in Table 
S1 in Supplementary Material. The cycling conditions used 
for execution of the mutagenic PCRs were as described before 
(36), but with varying extension times (Table 2), depending on 
the length of the fragment, optimized to favor the incomplete 
extension. The PCRs were performed on a ProFlex 3 × 32-well 
PCR System thermal cycler (Thermo Fischer Scientific). The 
amplified DNA fragments were subjected to DpnI (New England 
Biolabs) digestion for 2 h at 37°C. Following the digestion, the 
four PCR products were diluted three times with deionized 
water, then mixed unpurified in a ratio of 1:1:1:1, incubated at 
room temperature for 30 min to overnight and between 4 and 
10 µL of the mixture were transformed into One Shot TOP10 
chemically competent E. coli cells (Thermo Fischer Scientific), 
according to the manufacturer’s instructions. Successful clon-
ing was confirmed by Sanger sequencing (Source BioScience 
Sanger Sequencing Service, UK).
Production of Monoclonal antibodies
Expi293F cells were transfected with the pVitro1-hygro-mcs 
antibody construct using the ExpiFectamine293 Transfection 
kit (Thermo Fischer Scientific) as per manufacturer’s instruc-
tions. Transfection was carried out in Expi293 Expression 
Medium (Thermo Fischer Scientific). Supernatants of Expi293F 
cells transfected with an indicated antibody construct were 
harvested, spun down at 300 × g for 5 min and then at 3,100 × g 
for 40 min and filtered using a 0.45 µm membrane. For com-
parative studies, anti-CSPG4 WT IgG1 antibody (anti-CSPG4 
WT) was produced using the previously described HEK293-F 
method (36), as follows: starting with transient transfection and 
using 30 mL cultures in 125 mL shaker flasks for 2 weeks under 
Hygromycin B (Thermo Fischer Scientific) selection, those 
were subsequently scaled up to 500 mL in 1 L shaker flasks. The 
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supernatants were harvested after 2  weeks of stable antibody 
expression without antibiotic selection. Monoclonal antibodies 
were purified using Pierce™ Protein A Columns, 1 mL (Thermo 
Fischer Scientific). Antibodies were eluted using acetate elution 
buffer (0.58% glacial acetic acid, 0.15 M Sodium chloride) and 
neutralized with 120 µL neutralization buffer (1 M Tris, pH = 9). 
Purified antibodies were stored in PBS.
aleuria aurantia lectin (aal) Western blot
Purified antibody samples (500  ng) were mixed with 4× 
Laemmli buffer (Bio-Rad) containing 10% 2-mercaptoethanol 
and incubated at 95°C for 10 min. Subsequently, the reduced 
samples were run on 4–15% precast polyacrylamide gels (Bio-
Rad) and semi-dry blotted using the Bio-Rad Trans-Blot® 
Turbo™ Blotting System, according to the manufacturer’s 
instruction. The membrane was then cut into two just above 
35 kDa to separate the antibody heavy chain (50 kDa) and light 
chain (25 kDa), using the PageRuler prestained protein ladder 
(Thermo Scientific) as a reference. Next, the membrane con-
taining proteins above 35 kDa was blocked using Carbo-Free™ 
Blocking Solution (Vectorlab) and the one containing proteins 
below 35  kDa—in 5% bovine serum albumin (BSA) solution 
in PBS 0.05% Tween 20 (PBST). For probing, the over-35 kDa 
membrane was incubated with 0.2  µg/mL biotinylated AAL 
in Carbo-Free™ Blocking Solution for 1  h at room tempera-
ture and subsequently washed in PBST 3× for 10  min. Next, 
the membrane was incubated with horseradish peroxidase 
(HRP)-conjugated streptavidin (Thermo Fischer Scientific, 
1:30,000) for one hour, washed and developed with Enhanced 
Chemiluminescence (ECL, GE Healthcare). The under-35 kDa 
membrane was probed with rabbit anti-human-kappa light 
chain antibody (Abcam, 1:4,000) in PBST 5% BSA for 1  h at 
room temperature, washed and incubated with anti-rabbit-IgG 
HRP antibody (Cell Signaling Technology, 1:2,000), washed 
again, and developed as above. The results were analyzed using 
the ImageJ software.
Western blot semi-Quantitative analysis
The AAL signal values of the different protein bands (peak area) 
were normalized to the anti-kappa signal values (LC kappa). 
The AAL/LC kappa ratio values of anti-HER2 antibody variants 
were presented as a proportion (percentage) of the value of 
trastuzumab. Similarly, anti-CSPG4 antibody variant values were 
presented as a proportion of anti-CSPG4 WT.
evaluations of antibody Yields by elisa
IgG antibody expression by Expi293F cells was monitored using 
a sandwich enzyme-linked immunosorbent assay (ELISA). 
Briefly, Maxisorp 96-well plates (Thermo Fischer Scientific) 
were coated overnight with 0.5  µg/mL mouse anti-human 
IgG1 antibody (Bio-Rad) in carbonate buffer. On the next day, 
the plate was washed with PBS 0.5% Tween 20 (PBST) and 
unspecific binding was blocked using 2% skim milk in PBST 
(blocking buffer). Trastuzumab (Herceptin®, Roche) was used at 
as a standard at a starting concentration of 3 µg/mL. All samples 
were diluted (1:1,000) in blocking buffer and incubated on the 
plate overnight. The plates were developed on the next day, fol-
lowing an incubation with anti-human IgG-HRP (Sigma) at a 
dilution of 1:5,000, using o-Phenylenediamine dihydrochloride 
(Sigma) as the HRP substrate. Optical density was measured 
using Fluostar® Omega Spectrophotometer (BMG Labtech), at 
492 and 650 nm, the latter used to subtract background absorb-
ance. Standard curves were constructed on the Fluostar® Omega 
analysis software using a 4-parameter fit.
assessment of antibody binding to cells 
by Flow cytometry
Recognition of FcγRs on fresh peripheral blood NK  cells and 
of the target antigen on tumor cells by different anti-HER2 
and anti-CSPG4 antibody variants were assessed through flow 
cytometric binding assays. Cells were detached, as described 
above, re-suspended in staining buffer (PBS, 2% FCS) and incu-
bated in 96-well round-bottom plates (0.2 × 106 cells per well) 
on ice in the presence of the serially diluted antibody variants 
(concentration range 0.008–5  µg/mL) for 30  min on ice. The 
cells were subsequently washed and incubated with 1 µg per test 
FITC-conjugated goat anti-human IgG (Vector Laboratories Ltd.) 
on ice, for another 30 min. After one wash, cells were analyzed 
on a BD LSRFortessa™ (BD Biosciences), using the High 
Throughput Sampler (HTS) option. The BD Cytofix/Cytoperm™ 
(Becton Dickinson) kit was used according to the manufacturer’s 
instructions for Expi293F cell permeabilization and intracellular 
staining to detect antibody production. The results were analyzed 
using FlowJo software 7.6.5.
cell Proliferation assay
To determine the effect of anti-HER2 antibody variants on cell 
proliferation, 5,000 (BT-474) or 1,000 (SK-BR-3, MDA-MB-231, 
HCC1954) cells per well were plated in a 96-cell well tissue 
culture plates in complete medium and treated with the serially 
diluted antibodies (concentration ranges 0.0016–25  µg/mL). 
Cell proliferation was assessed after 96 (BT474, MDA-MB-231) 
or 120 h (SK-BR-3, HCC1954), using the CellTiter 96® Aqueous 
One Solution Cell Proliferation Assay kit (Promega), accord-
ing to the manufacturer’s instructions. Cell densities were 
measured using Fluostar® Omega Spectrophotometer (BMG 
Labtech).
antibody-Dependent cellular cytotoxicity 
(aDcc) assay
ADCC assays were performed using the HER2-overexpressing 
BT-474 cells as target cells and fresh peripheral blood NK cells 
as effector cells. NK cells and cancer cells were mixed at E:T 
ratio 10:1 (0.2 × 106 NK cells: 0.02 × 106 target cells) in RPMI 
GlutaMAX™ (Thermo Fischer Scientific) containing 2% FCS 
(Thermo Fischer Scientific). They were incubated in 96-well 
round bottom plates for 4  h (Thermo Fischer Scientific) in 
the presence of serially diluted anti-HER2 antibody variants 
or isotype control antibodies (at concentrations ranging from 
64  pg/mL to 5  µg/mL). Cellular cytotoxicity was assessed 
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using the Pierce LDH Cytotoxicity Assay Kit (Thermo Fischer 
Scientific), according to the manufacturer’s instructions. 
Absorbance read out was measured at 490 and 680 nm using 
Fluostar® Omega Spectrophotometer (BMG Labtech) and % 
cytotoxicity was calculated as per manufacturer’s instructions 
using the following formula:
 
% =
−
Cytotoxicity
Experimental value Effector Cells Spontaneous Control Target Cells
Target Cell Maximum Lysis Control Targe
−
− t Cells Spontaneous Control
100





 ×
 
Half maximal effective concentration (EC50) values at 
which different anti-HER2 Fc variant antibodies induced 
ADCC were calculated using the GraphPad Prism software 
(version 6, GraphPad Software Inc., USA). The data were 
normalized to a maximal (detergent induced) and minimal 
(isotype control) cell lysis and analyzed using a non-linear 
regression model.
calcium Flux assay
Freshly isolated human NK  cells were incubated with 1  nM 
Indo-1 calcium indicator (Thermo Fischer Scientific) for 30 min 
at 37°C in serum-free medium and subsequently washed and 
rested for 30  min in complete medium (42). Cells (1  ×  106 
cells per test) were incubated with anti-HER2 and anti-CSPG4 
antibody variants at 15 µg/mL for 30 min at 37°C, as above, and 
re-suspended in 500  µL RPMI GlutaMAX™ (Thermo Fischer 
Scientific). Before acquisition each sample was warmed up to 
37°C for exactly 5  min. The sample was acquired for 30  s to 
measure basal fluorescence, then the FcRs on the surface of the 
NK cells were crosslinked by adding 5 µg goat anti-human IgG 
F(ab′)2 (Thermo Fischer Scientific). Each sample was acquired 
for 5 min on BD LSRFortessa™ (BD Biosciences) with the violet 
laser (405  nm) turned off to avoid interference. Ionomycin at 
1 µg/mL was used as a positive control. Results were analyzed 
using FlowJo software version 8.7.
human specimens
Blood cone samples from anonymized donors were purchased 
from the National Health Service Blood and Transplant 
Service, United Kingdom. Sample processing was supported 
through a local ethical framework conducted in accordance 
with the Helsinki Declaration and approved by the NHS 
Research Ethics Committee, Guy’s and St. Thomas’ NHS Trust 
(“Immunopathogenesis and Molecular Biology in Breast Cancer 
Subtypes,” REC reference number: 13-LO-1248).
resUlTs
antibody Fc region Manipulation Design
First, we devised a cloning strategy that allows the manipulation 
of monoclonal antibody Fc regions in order to influence FcRs 
binding properties and consequently antibody effector functions. 
Alongside WT equivalents, we generated Fc-mutant variants 
designed either to have diminished or enhanced binding to 
FcRs on human immune effector cells, and we exemplified this 
strategy by engineering panels of antibody clones that recognize 
two cancer-associated antigens.
We initially employed WT IgG1 antibody heavy and light 
chain fragments incorporated in pVitro1-hygro-mcs vectors 
(Figure 1A). We then utilized these vectors as templates in four 
separate PIPE PCRs in order to generate linear fragments carrying 
specific Fc region point mutations (Figures 1B,C). Point muta-
tions were introduced using mutagenic PIPE primers (Table 1; 
Table S1 in Supplementary Material). Mutations were designed 
to either reduce [N297Q (NQ), Figure 1B] or enhance [S239D/
I332E (DE), Figure  1C] binding of the antibody Fc to FcγRs 
(Fc gamma receptors) on human effector cells. Since Asn297 is 
a conserved glycosylation site for the human IgG1 Fc domain, 
we mutated this to Gln. This is expected to lead to aglycosylation 
and a conformational change which can impair binding to FcγRs 
(26, 28). By contrast, we designed S239D/I332E (DE) mutated 
IgG1 Fc regions to have increased binding to the FcγRIII com-
pared to WT IgG1 antibodies.
To generate the N297Q mutant antibody variants designed 
to have reduced binding to FcRs (Figure 1B), we linearized the 
pVitro1 WT constructs through PIPE PCR (see Table 1 for primer 
pairs), yielding Fragments 1, 2, 3, and 4. Fragment 1 was gener-
ated to carry CAG (Q) instead of AAC (N) at positions 889–891. 
Shortened extension times and lack of final extension step favored 
the PIPE process during the PCR. Therefore, the Fragment 1 final 
product had 5′ PIPE overhangs (“sticky ends”) but also carried 
the desired CAG codon. Similarly, we generated Fragment 4 with 
5′ overhangs and the desired mutated codon. The other two frag-
ments, Fragment 2 and Fragment 3, were as well amplified with 
5′ PIPE overhangs but without point mutations.
The S239D/I332E mutants designed to yield antibodies with 
enhanced FcR binding were generated in a similar manner 
(see Table 1 for primer pairs). The pVitro1 WT constructs were 
linearized through PIPE PCR to favor the occurrence of sticky 
ends for PIPE cloning (Figure 1C). All fragments were amplified 
with PIPE 5′ overhangs; however, Fragment 1 carried both the 
GAC (D) codon instead of the WT TCA (S) codon, and the GAA 
(E) codon instead of the WT ATC (I) codon (positions 877–879 
and 994–996, respectively); Fragment 2 carried the GAA (E) 
codon instead of ATC (I) codon; and Fragment 4 carried GAC 
(D) codon instead of TCA (S) codon.
The primers used for the generation of both N297Q (NQ) and 
S239D/I332E (DE) Fc mutants are designed to be universal and can 
be used for the generation of NQ and DE mutant versions of any IgG1 
antibody cloned into pVitro1-hygro-mcs (see Table 2 for lengths of 
the pVitro1 PIPE fragments and extension times for amplifications).
Following amplification, linear pVitro1 fragments were 
treated with DpnI enzyme to digest any remnants of the pVitro1 
WT construct used as a template in the PCR (Figure 1D). All four 
fragments were then mixed together unpurified, thus eliminating 
FigUre 1 | Schematic representation of the pipeline for generation and production of wild-type (WT) and Fc mutant IgG antibodies. (a) WT antibody construct in 
pVitro1-hygro-mcs. (b) Polymerase incomplete primer extension (PIPE) PCR linearization and mutagenesis of the WT construct to generate pVitro1 DNA fragments 
carrying the N297Q (left, fragments 1 and 4) or S239D/I332E (right, fragments 1, 2, and 4) mutations. Mutations indicated by “*”. (c) Introduction of mutations in WT 
constructs through mutagenic PIPE primers. (D) DpnI digestion. (e) Enzyme-independent assembly of the linear pVitro1 fragments. (F) Bacterial transformation of 
the assembled constructs. (g) Confirmation of the insertion of desired mutations. (h,i) Recombinant expression in Expi293F cells (h) and purification (i) of antibody 
WT and mutant variants.
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FigUre 2 | Agarose gel electrophoresis of polymerase incomplete primer extension (PIPE) PCR fragments for the generation of anti-HER2 and anti-CSPG4 N297Q 
(NQ) and S293D/I332E (DE) Fc mutant IgG1 antibodies. O’Generuler™ 1 kb DNA ladder (Thermo Fischer Scientific) was used as a molecular weight marker. The 
lanes labeled F1–4 represent the NQ and DE PIPE PCR fragments 1–4, depicted in Figure 1. The expected molecular weights (in bp) of each fragment are listed in 
Table 2.
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the need to perform PCR clean up or to use ligation enzymes. The 
mixtures were incubated at room temperature (Figure 1E) and 
transformed into competent bacteria (Figure 1F). Correct trans-
formants were verified through Sanger sequencing (Figure 1G). 
Expi293F cells were transfected with the pVitro1 mutant con-
structs in 30 mL working volumes (Figure 1H) and antibodies 
were secreted in culture supernatants (Figure 1I).
Overall, this strategy facilitates the manipulation of mono-
clonal antibody Fc regions to allow the generation of mutant 
versions of any IgG1 antibody clone.
generation of anti-her2 and anti-csPg4 
n297Q and s293D/i332e igg1 Mutant 
constructs
Using our pipeline, we generated WT, N297Q (NQ), and S293D/
I332E (DE) mutant antibodies recognizing two cancer antigens 
(i) the human epidermal growth factor receptor 2 (HER2/neu) 
(3), known to be overexpressed by 25% of breast carcinomas and 
(ii) the CSPG4, reported to be overexpressed in 70% of melanomas, 
a proportion of triple-negative breast cancers, and other solid 
tumors (41, 43, 44). In order to produce anti-HER2 IgG1 WT 
antibody, we used the variable regions of the 4D5-8 therapeutic 
antibody clone (trastuzumab) (2, 4, 45). The sequence was manu-
ally codon-optimized (Figure S1 in Supplementary Material), and 
cloned into the pVitro1-hygro-mcs vector (36). The anti-CSPG4 
IgG1 WT construct was derived using the variable regions of a 
murine antibody (46) and cloned into pVitro1-hygro-mcs (36). 
The pVitro1 WT constructs were used as templates for the gen-
eration of the corresponding mutant variants. The DNA products 
of the mutagenic PIPE PCRs were visualized using agarose gel 
electrophoresis (Figure 2), confirming that the fragments were 
of the expected sizes.
All four mutant constructs were successfully cloned on first 
attempt and between 1 and 15 colonies were analyzed for the 
different constructs (Table S2 in Supplementary Material). The 
desired mutations were present in all the screened plasmids (each 
purified from a single colony) and no background contamination 
with the WT construct was observed. These findings suggest high 
mutagenesis efficiency for this cloning approach.
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Optimized antibody Production with  
the expi293F expression system
We produced monoclonal antibodies both by using a previously 
described HEK293-F system as well as by employing the cloning 
approach described herein with the human embryonic kidney 
derivative cell line Expi293F. Antibody production with the 
previous method in HEK293-F cells was initiated using 30 mL 
shaker flask cultures under selection for 2 weeks, followed by a 
2-week scale up to 500 mL shaker flask cultures. With the previ-
ous platform, after 4 weeks, we obtained an average of 13 µg/mL 
of anti-CSPG4 WT (by ELISA). By contrast, using the present 
transient expression Expi293F platform, we produced an average 
of 130 µg/mL anti-CSPG4 WT and 160 µg/mL anti-HER2 WT 
antibodies using only 30 mL shaker flask cultures volumes within 
5–7 days post-transfection (detected by ELISA) (Figure 3A).
To evaluate the rate of transfection efficiency, we used flow 
cytometry to analyze the expression of IgG by permeabilized 
Expi293F cells 3 days after transfection with the anti-HER WT, 
DE, and NQ constructs (Figure 3B). A large proportion (≥98%) 
of transfected Expi293F cells was positive for human IgG, indica-
ting a high transfection efficiency rate. To investigate whether the 
addition and timing of antibiotic selection (Hygromycin B) to 
Expi293F cell cultures could affect antibody yields, we expressed 
anti-HER2 WT antibody with or without the addition of 
Hygromycin B at different times following transfection and found 
that addition of Hygromycin B did not affect purified anti-HER2 
antibody yields (Figure 3C). To then determine the optimal time 
to harvest the supernatants, we monitored the concentrations 
of anti-HER2 WT and anti-CSPG4 WT antibodies over time by 
ELISA. For both antibodies, the maximum production yields were 
reached between 5 and 7 days post-transfection (Figure 3D).
We then measured total antibody yields by Expi293 cells after 
purification of anti-HER2 and anti-CSPG4 variants. We obtained 
an average of 56  µg/mL anti-HER2 DE, 62  µg/mL anti-HER2 
NQ (Figure 4A, left), 44 µg/mL anti-CSPG4 DE, and 73 µg/mL 
anti-CSPG4 NQ (Figure 4A, right). We then confirmed that Fc 
mutations did not impair the binding of antibodies to protein 
A used for antibody purification: no significant differences 
in protein yields of either anti-HER2 DE (Figure  4B, left) or 
anti-HER2 NQ variants (Figure 4B, right) were measured after 
purification by protein A column, or by KappaSelect column, 
which binds antibody kappa light chains. We concluded that 
none of the mutations could alter antibody binding to either 
matrix and, thus, the purification method did not appear to 
influence antibody yields.
Next, the integrity and purity of different anti-HER2 and 
anti-CSPG4 antibody variants were confirmed through sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
under non-reducing (Figure 4C, top) and reducing (Figure 4C, 
bottom) conditions. All antibodies migrated according their 
expected approximate molecular weights of ~150  kDa (non-
reducing conditions) and no other contaminating proteins or 
antibody fragments were observed. Under reducing conditions, 
the heavy chains of the WT and DE variants of both antibodies 
migrated according to the expected molecular weight of 50 kDa. 
Anti-HER2 and anti-CSPG4 NQ variants exhibited increased 
mobility compared with the WT and DE analogs, in accordance 
with previous reports (28). The light chains of all the variants were 
found to be of the expected size of 25 kDa.
To ascertain whether different Fc mutations influence glycosyla-
tion and to simultaneously evaluate the fucosylation patterns of the 
anti-HER2 and anti-CSPG4 variants, we probed purified antibody 
samples with AAL (fucose specific, Figure 4D). We used an anti-
human kappa chain antibody as a loading control (Figure  4D, 
bottom strips). We observed no AAL signal with the anti-HER2 
and anti-CSPG4 NQ variants, confirming that the introduced 
N297Q amino acid substitution has resulted in lack of core glyco-
sylation (Figure 4D, top panel). We performed semi-quantitative 
analysis of the AAL Western blot data using the ImageJ software 
(Figure 4E). The values obtained with the NQ variants were close 
to background. No significant differences were observed between 
WT and DE mutant antibodies (both anti-HER2 and anti-CSPG4 
variants). These findings suggest that mutating the Fc region of IgG1 
at position 297 disrupts a conserved glycosylation site, most likely 
eliminating core glycosylation, while mutations at positions 293 and 
332 do not affect the decoration of the core glycan with fucose.
Therefore, we confirmed the implementation of an optimized 
Expi293F expression platform with additional features and 
which outperforms that previously reported. Key attributes are 
five-fold: namely (i) provision for generation of mutant antibody 
variants; (ii) high mutagenesis efficiency; (iii) high transfection 
efficiency (eliminating the need for antibiotic selection); (iv) up 
to 10-fold higher antibody yields in ~17-fold smaller (30  mL) 
culture volumes; and (v) 3-fold reduced time frame (12 days) for 
implementation from concept to purified antibody (Table 3).
Fc Mutants retain Fab-Mediated binding 
to antigens but exhibit Differential  
Fc-Mediated receptor recognition 
compared with WT antibodies
We next investigated the target antigen recognition and binding 
properties of engineered antibody variants against different cancer 
cell lines expressing cell surface HER2 (Figure 5A; Figure S2 in 
Supplementary Material) or CSPG4 (Figure 5B). All HER2 vari-
ants recognized HER2 on BT-474 (top left), SK-BR-3 (top right), 
ZR-75-30 (bottom left) and HCC1954 (bottom right) breast can-
cer cell lines, and bound in a dose-dependent manner and with 
comparable kinetics to the commercially produced trastuzumab 
(Herceptin®, Roche). Similarly, for the engineered antibodies 
recognizing CSPG4 (Figure 5B), no differences were observed in 
their binding characteristics to the CSPG4-overexpressing CSPG4 
knock-in MDA-MB-231 (top left), and natural lower-expressing 
MDA-MB-231, HTB-26 (top right), Hs 578T (bottom left), and 
BT549 (bottom right) breast carcinoma cell lines.
We then investigated the binding characteristics of anti-HER2 
and anti-CSPG4 Fc variants to FcγRIII, the Fcγ receptor expressed 
by NK cells (47) (Figure 5C). Fluorescence intensities observed 
for human peripheral blood NK cells incubated with anti-HER2 
(top) and anti-CSPG4 (bottom) NQ variants were similar to 
those measured for the secondary anti-human kappa chain 
APC-conjugated antibody control at all concentrations tested, 
suggesting that the NQ mutation resulted in impaired binding 
to FcγRIII. Binding of the WT anti-HER2 antibodies, including 
FigUre 3 | Cell transfection and antibody expression. (a) Schematic comparison of previously reported HEK293-F and the Expi293F expression systems with 
regard to required time, process, culture volumes, and antibody yields. (b) Flow cytometric dot plots depicting percentage of human IgG positive Expi293F cells 
3 days post-transfection with anti-HER2 constructs. Cells were permeabilized and stained with anti-human IgG FITC; untransfected Expi293F cells (unstained and 
stained) were used as controls. (c) Effect of antibiotic selection addition at different times post Expi293F transfection with anti-HER2 wild-type (WT) construct—
post-purification yields per mL of cell culture supernatant. Data from two independent experiments ± SD. (D) Concentration of WT anti-HER2 and anti-chondroitin 
sulfate proteoglycan 4 (CSPG4) antibodies per mL of cell culture supernatant over time measured by enzyme-linked immunosorbent assay. Data from two 
independent experiments ± SD.
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the commercially available trastuzumab (Herceptin®) to human 
NK cells were detected only at the highest concentrations tested 
(1 and 5 µg/mL). Similarly, the anti-CSPG4 WT antibody only 
bound to NK cells at high (5 µg/mL) concentrations. By contrast, 
the anti-HER2 and anti-CSPG4 DE variants displayed up to 
7-fold (anti-HER2) and 17-fold (anti-CSPG4) higher binding to 
FcγRIII on NK cells compared with binding of WT antibodies at 
5 µg/mL concentrations to FcγRIII (Figure 5C).
Table 3 | Characteristics of the Expi293F vs. the HEK293-F cloning/expression 
platforms.
expression host expi293F heK293-F
Wild-type (WT) antibody polymerase 
incomplete primer extension (PIPE) cloning
Yes Yes
Generation of Fc mutants Yes No
Expression culture conditions Serum free 10% FBS
Expression system type Transient Stable
Antibody concentration (sup) 130 µg/mL  
(anti-CSPG4 WT)
13 µg/mL  
(anti-CSPG4 WT)
Working culture volume (expression) 30 mL 500 mL
Time required for cloning/sequencing verification 3 days 3 days
Time required for large scale plasmid DNA 
production/transfection
2 days 2 days
Time required for expression/purification 1 week 4 weeks
Total time required (whole platform) 12 days 33 days
FigUre 4 | Purified antibody evaluations. (a) Wild–type (WT) and mutant anti-HER2 and anti-CSPG4 antibody yields per mL of cell culture supernatant after 
purification (data from two independent experiments ± SD). (b) Comparison of anti-HER2 mutant antibody yields after purification using HiTrap Kappa Select  
(GE Healthcare) or Protein A (Pierce™) columns. (c) Sodium dodecyl sulfate polyacrylamide gel electrophoresis visualization of purified anti-HER2 and anti-
chondroitin sulfate proteoglycan (CSPG4) WT and Fc mutant antibodies under non-reducing (top) and reducing (bottom) conditions. PageRuler™ pre-stained 
protein ladder (Thermo Fischer Scientific) was used as molecular weight reference. Bands were visualized using InstantBlue™ protein stain (Expedeon). (D) Aleuria 
Aurantia Lectin (AAL) Western blot demonstrating fucosylation patterns of anti-HER2 (top left) and anti-CSPG4 (top right) Fc variants. Anti-human kappa chain 
antibody was used as a loading control (bottom panels). (e) Quantification of AAL Western blot signal using the ImageJ software. The AAL signal was normalized 
against the signal obtained with the anti-kappa chain antibody. The ImageJ peak area value of trastuzumab (Herceptin®, Roche) was considered a 100% and the 
peak area values of the other anti-HER2 variants were presented as a proportion of the first value. The values of anti-CSPG4 DE and NQ were calculated 
accordingly as a proportion of anti-CSPG4 WT. Data from three independent experiments ± SD.
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These findings suggest that while Fc-mutated antibodies retain 
Fab-mediated recognition of target antigen-expressing cancer 
cells, DE mutant antibodies have enhanced, and NQ mutants 
have diminished binding to FcγRIII on human primary NK cells 
compared with their WT equivalents.
De Mutant antibodies have enhanced, 
While nQ Mutants have Diminished ability 
to induce Fc-Mediated activation of nK 
cells compared with WT antibodies
To further assess the ability of antibody variants to engender 
NK effector cell activation through engagement of FcγRIII, we 
measured calcium ion influx by cross-linking with polyclonal 
anti-IgG antibodies to mimic immune complex formation. 
FigUre 5 | Antibody target antigen and Fc receptors (FcRs) binding evaluations. (a) Target antigen recognition of anti-HER2 Fc variants on HER2-overexpressing 
cancer cell lines. All anti-HER2 Fc variants including the positive control trastuzumab (Herceptin®, Roche) bound to the target antigen in a similar dose-dependent 
manner. (b) Target recognition of anti-chondroitin sulfate proteoglycan 4 (CSPG4) Fc variants on triple-negative breast cancer cell lines. All the anti-CSPG4 Fc 
variants bound to the target antigen in a similar dose-dependent manner. (c) Left: binding of anti-HER2 (top) and anti-CSPG4 (bottom) Fc variants to FcγRIII on 
fresh human peripheral blood NK cells with increasing antibody concentrations (0.008–5 µg/mL). Right: flow cytometric histograms depicting antibody binding at 
saturating concentrations (5 µg/mL). Graphs are representative of two independent experiments; data were normalized against an isotype control (a,b) or 
secondary antibody control (c).
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No calcium flux was detected in cells not treated with cross-linker 
(Figure 6A, top). The levels of calcium flux following cross-linking 
of WT antibodies [anti-HER2 WT, trastuzumab (Herceptin®), 
anti-CSPG4 WT] and NQ antibodies (anti-HER2 NQ and 
anti-CSPG4 NQ) were all comparable to background levels of 
control samples given cross-linker only to engage endogenous 
IgG (Figure 6). On the other hand, cross-linking of either anti-
HER2 DE or anti-CSPG4 DE antibody variants triggered higher 
intracellular calcium mobilization compared with all other anti-
bodies (Figure 6). These findings, confirmed with NK cells from 
different human donors (Figure S3 in Supplementary Material), 
are consistent with the higher binding attributes of DE mutant 
variants to FcRIII on NK cells (Figure 5C).
anti-her2 Variants retain Their ability  
to inhibit her2-Overexpressing cancer 
cell Proliferation but Differ in Their 
Potency to Trigger nK cell-Mediated 
anti-Tumor Functions
Trastuzumab (Herceptin®) has been reported to directly inhibit 
the proliferation of HER2-over-expressing cell lines (1, 2, 4, 48). 
FigUre 6 | Antibody Fc-mediated calcium mobilization of human NK cells. (a) Flow cytometric dot plot graphs of Ca++ flux assay measurements showing activation 
of NK cells pre-incubated with different anti-HER2 Fc (left) and anti-chondroitin sulfate proteoglycan 4 (CSPG4) (right) Fc variants after cross-linking with a polyclonal 
anti-IgG antibody. Ca++ flux into the cells was visualized through the increase in the DAPI/Indo-1 (blue) ratio over time. (b) Histogram overlay demonstrating the 
differences in Ca++ influx between different anti-HER2 (left) and anti-CSPG4 (right) antibody variants depicted as the changes in the DAPI/Indo-1 Blue fluorescence 
ratio over time. The top overlays include all antibody variants and controls and the bottom exclude the ionomycin control to more clearly demonstrate the differences 
between the antibody variants on a smaller scale. Data representative of three independent experiments.
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We, therefore, examined whether these attributes are retained 
by the anti-HER2 Fc variants. WT and mutant anti-HER 
inhibited the proliferation of the HER2-overexpressing BT-474 
and SK-BR-3 breast cancer cells in a dose-dependent manner, 
and with comparable potency to those of the clinically available 
trastuzumab (Herceptin®). None of the variants could reduce 
the proliferation of the low HER2-expressing triple-negative 
MDA-MB-231 or of the trastuzumab-resistant HCC1954 breast 
cancer cell lines (Figure 7A) (49). We, therefore, concluded that 
Fc-engineered antibodies can retain the direct Fab-mediated 
effects of the original unmodified clone.
A known anti-tumor mechanism of action of trastuzumab 
(Herceptin®) is the ability to trigger antibody-dependent cellular 
cytotoxicity (ADCC) of HER2-expressing cancer cells mediated 
by NK cells (11, 50). Therefore, we studied the potency of different 
anti-HER2 Fc variants to induce tumor cell cytotoxicity (ADCC) 
of the HER2-overexpressing BT-474 cells (target cells) mediated 
by fresh peripheral blood NK cells from three different donors 
(effector cells) (Figure  7B) (51–53). The in-house produced 
anti-HER2 WT antibody and trastuzumab (Herceptin®) showed 
similar tumor cell killing potencies mediated by NK cells from all 
three human donors. Anti-HER2 DE induced higher tumor cell 
killing at significantly lower concentrations than WT antibod-
ies. All antibodies showed similar levels of ADCC at saturating 
concentrations (5  µg/mL). In line with diminished binding to 
FcγRIII on the surface of NK cells, the anti-HER2 NQ mutant 
IgG1 failed to induce any tumor cell killing above controls (EC50 
of variants for each independent experiment, Figure 7C).
Furthermore, we tested the potency of anti-HER2 variants to 
trigger NK cell-mediated ADCC against cancer cells that express 
low levels of the target. We chose the triple-negative breast can-
cer cell line MDA-MB-231 known to express very low levels of 
HER2/neu (Figure 7D), and the HER2-overexpressing cell line 
BT-474 to compare the effects of the target expression on ADCC 
levels induced by NK  cells from the same donors (Figure  7D, 
Donors 4 and 5). We observed no or very low ADCC against 
MDA-MB-231 with all the variants (Figure 7, top panels), while 
against BT-474, anti-HER2 DE, WT, and trastuzumab induced 
dose-dependent tumor cell lysis (Figure  7D, bottom panels), 
consistent with the findings depicted in Figure 7B.
Therefore, while antibody Fab-mediated direct effects are not 
affected, Fc-modified antibody variant engineering allows the 
manipulation of antibody binding kinetics to effector cells, and 
can alter antibody functional capacity and potency to mediate 
immune effector cell activation and NK cell-mediated cytotoxic-
ity of tumor cells.
DiscUssiOn
With monoclonal antibody therapies firmly established as part 
of the standard care of treatment for solid tumors and hemato-
logical malignancies (54–56), designing antibodies to engender 
well-defined Fab-mediated and Fc-mediated anti-cancer proper-
ties is highly desirable. Specifically, Fc-mediated effects can have 
a major impact on the ability of antibodies to engage cells of the 
immune system and can influence their anti-tumor functions 
and efficacy.
Here, we designed and implemented a novel seamless cloning 
and expression platform for the generation of a panel of anti-
cancer monoclonal antibodies with modified human Fc regions. 
We evaluated the functional impact of antibody engineering on 
antibody Fab- and Fc-mediated functions. This strategy allows 
the generation of WT and Fc mutant antibodies of any specificity 
at high mutagenesis and transfection efficiency, short time frames 
for cloning and production, and high yields of pure material. 
Compared to WT antibodies produced using a previous cloning 
approach, this represents 10-fold increased yields at a 3-fold 
reduced time frame of 12 days from design to purified antibody 
material (Table  3). This approach permits the generation of 
Fc-modified variants of any antibody clone and may find wide 
applications in antibody engineering and functional screening.
Compared with existing mutagenesis cloning methods, 
our approach is unique in combining the following features: 
(i) high efficiency; (ii) no need of restriction or ligation enzymes; 
(iii) requirement for only a single step PCR; (iv) designed for 
mutagenesis/cloning of large expression ready plasmid constructs; 
(v) employs universal primers which could be applied to any IgG1 
antibody construct; and (vi) applicability for the generation of 
different versions of the same antibody construct (36, 37, 40, 57). 
These features, combined with rapid, small volume, and high yield 
transient expression in mammalian Expi293F cells constitute a 
unique and novel methodology which can facilitate selection of 
therapeutic antibody candidates with the most suitable attributes 
by employing mechanistic and potency evaluations.
While all antibody variants retained recognition of target 
antigens expressed on tumor cells, engagement of FcγRs on 
human primary NK  cells was affected in Fc-mutated variants. 
The DE and NQ mutants showed enhanced and diminished 
binding properties, respectively, compared with binding of WT 
antibodies, consistent with previous findings (58). Here, binding 
studies of the Fc variants were conducted by flow cytometry 
on natively expressed FcRs and in the presence of endogenous 
immunoglobulins on the surface of fresh human NK cells. Hence, 
our 7- to 17-fold increased affinity of the DE variants compared 
with native antibodies may underestimate absolute increased 
affinities, previously measured with recombinant FcγRIIIa (58). 
Furthermore, although we engineered our antibody panels for 
each clone to be of the same isotype, with identical Fc region 
sequences, we observed that DE mutations improved the bind-
ing of anti-CSPG4 to NK  cells more than the same mutations 
improved the binding of anti-HER2 enhanced DE variant. It is 
possible that these differences may depend on the antibody Fab 
regions and that mutating Fc regions in an identical way could still 
result in different Fc-mediated properties for different antibodies 
and merits further study. We also found differences in enhanced 
binding between DE and WT antibodies with different donors. 
It is, therefore, possible that enhanced kinetics would also be 
subject to donor-dependent effects and this requires investigation.
When we interrogated antibody Fc-mediated NK  cell acti-
vation, we found enhanced calcium mobilization by mutant 
antibodies with high FcR-binding attributes. Furthermore, we 
observed low levels of Calcium influx triggered by endogenous 
IgGs on the surface of NK cells, which did not increase after the 
cells were incubated with WT antibodies. This may represent a 
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FigUre 7 | Continued
FigUre 7 | Continued  
Assessments of direct and Fc-mediated effects of anti-HER2 Fc variants against breast cancer cells. (a) Effects of anti-HER2 antibody variants on the proliferation of 
trastuzumab-sensitive (BT-474, SK-BR-3), trastuzumab-resistant (HCC1954) and triple-negative (MDA-MB-231) breast cancer cell lines. Anti-HER2 variants inhibited 
the proliferation of BT-474 and SK-BR-3 cells in a similar dose-dependent manner, but did not affect the proliferation of MDA-MB-231 or HCC1954 cells. Graphs 
represent an average of two experiments ± SD. (b) Human peripheral blood NK cell-mediated ADCC of BT-474 cancer cells induced by anti-HER2 variants 
measured by LDH release. Graphs are representative of independent experiments with three different human NK cell donors; data were normalized to minimal and 
maximal cell lysis. Error bars represent SEM values from technical replicates. N/D: not detected. (c) Effective concentration [(EC50) nM] measurements of ADCC by 
three human NK cell donors. (D) NK cell-mediated ADCC (measured by LDH release) of HER2 low (MDA-MB-231) and HER2 high (BT-474) breast cancer cells 
induced by anti-HER2 variants. The flow cytometric histograms on the left depict HER2 expression levels in MDA-MB-231 (top) and BT-474 (bottom) compared to 
unstained cells or cells stained with isotype control mAb. The graphs represent total cell killing levels of MDA-MB-231 cells (top) and BT-474 cells (bottom) mediated 
by NK cells from two different donors (Donors 4 and 5) at different concentrations of anti-HER2 variants.
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picture close to the physiological conditions, where WT thera-
peutic antibodies would have to compete with endogenous IgGs 
with similar affinities for their cognate Fcγ receptors. This may be 
addressed through increasing the affinity of therapeutic antibod-
ies to CD16 (59).
We demonstrated that while all anti-HER2 antibody variants 
retain their Fab-mediated direct effects in restricting HER2-
expressing breast cancer cell proliferation, Fc-modified anti-HER2 
antibodies engender differential anti-tumor cell cytotoxicity 
potencies by human NK cell effectors. Fc engineering may, there-
fore, provide a means of manipulating antibody binding kinetics 
to effector cells, and can alter the antibody’s functional capacity 
and potency to mediate immune effector cell activation and cell-
mediated cytotoxicity.
Even though there are conflicting reports about the ability 
of trastuzumab to trigger NK  cell-mediated killing in low 
HER2-expressing cancer cells, in this study, we observed very 
low ADCC activity of anti-HER2 variants against cancer cells 
expressing low levels of the target antigen (51, 60). Although this 
may indicate the likely inability of Fc engineered antibodies to 
target low tumor antigen-expressing cancer cells, these findings 
could also be interpreted as favorable in terms of potential safety 
of clinical application of Fc-optimized anti-HER2 antibodies. 
By targeting high-expressing tumor cells but not low HER2-
expressing normal tissues, such as cardiomyocytes, their applica-
tion may engender anti-tumor effects in the absence of on-target, 
off-tumor toxicities (61).
We confirmed that our generated N297Q mutants com-
pletely lack fucosylation. The N297Q mutation most likely 
results in loss of the core glycan, previously reported to alter 
the “open” conformation of WT IgG1 antibodies in favor of a 
“closed” confirmation, leading to impaired ability to engage 
FcRs (26). On the other hand, loss of fucose from the N-linked 
core glycan can substantially improve IgG binding to FcγRIIIA 
and ADCC. Therefore, differences in the glycosylation of opti-
mized Fc mutants may contribute to their ability to outperform 
their WT counterparts in FcR engagement and effector cell 
activation (62). In this study, we demonstrate that the enhanced 
FcR and Fc-mediated functional attributes of the S293D/I332E 
mutants are not linked to differential fucosylation. The exact 
mechanisms behind this functional superiority are currently 
unknown; unraveling these would require further in-depth 
structural, interaction, and functional studies.
The importance of engineering monoclonal antibodies with 
defined Fc functions is highlighted by findings of reduced 
clinical responses to monoclonal antibodies, such as cetuximab 
(anti-EGFR), trastuzumab (anti-HER2), and rituximab (anti-
CD20), in individuals who carry FcR polymorphisms that alter 
antibody binding affinities to immune effector cells (63–67). 
Different approaches have been developed to enhance the 
potency of monoclonal antibodies in activating effector cells 
against cancer (21). Optimization of IgG Fc domains through 
introduction of point mutations or glyco-engineering can influ-
ence binding kinetics to FcR. Fc mutant versions of trastuzumab 
(anti-HER2), alemtuzumab (anti-CD52), rituximab (anti-CD20), 
and others have shown significantly improved binding to FcγRs 
and enhanced effector functions (58, 68). Since removal of 
fucose from the N-linked core glycan can dramatically improve 
IgG–FcγRIIIA interactions and ADCC of tumor cells (62), two 
afucosylated antibodies (obinutuzumab and mogamulizumab) 
are approved for clinical use in hematological oncology (69, 70). 
An important reported advantage of certain Fc-optimized 
therapeutic antibodies is that they exhibit enhanced binding 
to FcγRIIIA even in the presence of polymorphisms that oth-
erwise lower affinity for IgG (58, 64). In this aspect, a future 
development of our platform could include functional studies 
of the capacity of Fc-optimized variants to activate NK  cells 
with defined FcγRIIIA genotype. Specific Fc mutations can also 
improve antibody pharmacokinetic characteristics through 
improved binding to the neonatal FcR, FcRn (21). Experimental 
approaches also entail switching the antibody isotype from the 
traditionally preferred IgG (mainly IgG1) to other isotypes, such 
as IgA or IgE, which could also provide advantages through 
alternative immune surveillance properties in specific tissues 
and through activating immune effector cell types that may be 
different to those engaged by IgG (18, 45, 71–74).
In this study, we also generated IgG1 antibody variants with 
vastly reduced FcR engagement and with impaired effector 
functions. Abrogation of antibody binding to FcRs and abolition 
of Fc-mediated effector functions is a useful approach for the 
design of antibodies with direct agonistic or antagonistic activi-
ties, antibody–drug conjugates or checkpoint blockade inhibitor 
antibodies. In some cases, effector cell engagement may not 
always be desirable, may impede Fab-mediated effects or bear 
safety hazards if intact Fc-mediated effector functions are retained 
(22, 23, 25, 75). Antibodies of the IgG2 or IgG4 isotypes are tradi-
tional choices in such drug design strategies. Nevertheless, IgG2 and 
IgG4 antibodies may not completely lack effector cell engagement 
(76). Furthermore, the latter may retain the potential to interact 
with other IgG Fc domains or undergo Fab arm exchange (FAE) 
which can lead to reduced activity or off-target effects (24). Efforts 
have, therefore, focused toward abolishing Fc-mediated functions 
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to avoid potentially dangerous immune-mediated toxicities. 
In addition, monoclonal antibodies used for cancer therapy are 
often associated with a range of adverse reactions including trig-
gering cytokine storm or hypersensitivity responses (22, 23). Where 
the purpose of the therapy is to engender Fab-mediated functions 
(25), complete abrogation of Fc effector capabilities could often be 
a necessity for certain antibody therapeutic design applications.
Monoclonal antibodies of the same immunoglobulin isotype 
recognizing different cancer antigens often act through different 
immune-mediated mechanisms. The same Fc-modifications may 
engender different effector properties by antibodies with vari-
able specificities and affinities to different antigens or antigenic 
epitopes. In this context, our approach provides a convenient 
tool to enable investigation of the effects of Fc point mutations 
on the function of monoclonal antibodies of any specificity. 
To exemplify this, we quickly generated Fc variants of monoclonal 
antibodies against two tumor-associated antigens, with which we 
were able to delineate antibody Fab-mediated and Fc-mediated 
mechanisms of action. This demonstrated the capability of the 
system to enable control of effector functions through introduc-
tion of point mutation capabilities. The universal nature of the 
Fc modification features built into our approach opens the door 
toward the generation of a range of Fc variants of antibodies of 
any specificity. Furthermore, serum-free production and quick 
high antibody yields could provide sufficient high quality mate-
rial to facilitate early in vitro and in vivo screening, downstream 
translation to good manufacturing practice (GMP) pathways and 
facilitate potential clinical application.
In summary, with this design strategy, we are able to manipu-
late anti-cancer antibody Fc regions. We delineate the binding and 
functional attributes of WT and Fc-modified agents and evaluate 
their Fab-mediated and Fc-mediated functions and potency. This 
approach can find broad application in therapeutic antibody 
engineering and translation for cancer therapy and potentially in 
other areas beyond the cancer immunotherapy field.
eThics sTaTeMenT
Blood cone samples from anonymized donors were purchased 
from the National Health Service Blood and Transplant Service, 
United Kingdom. Sample processing was supported through 
a local ethical framework conducted in accordance with the 
Helsinki Declaration and approved by the NHS Research Ethics 
Committee (Van Cutsem et al.), Guy’s and St. Thomas’ NHS Trust 
(“Immunopathogenesis and Molecular Biology in Breast Cancer 
Subtypes,” REC reference number: 13-LO-1248).
aUThOr cOnTribUTiOns
KI, SK, and AT conceived and designed the study. KI, JF-S, TD, 
SM, SC, PK, and IC helped with the development of the method-
ology. KI, JF-S, DA, TD, SM, SC, HB, AC, PK, and IC acquired the 
data or helped with the data analysis and interpretation. KI, JF-S, 
DA, SM, SC, HB, PK, MF, RM, DJ, AB, JM, JS, EJ-J, AT, and SK 
discussed and interpreted the data and edited the manuscript. SK 
and AT supervised the study. SK led and coordinated the project. 
KI and SK wrote the manuscript.
acKnOWleDgMenTs
We acknowledge the Biomedical Research Centre Immune 
Monitoring Core Facility team at Guy’s and St. Thomas’ NHS 
Foundation Trust for assistance.
FUnDing
The authors acknowledge support by Breast Cancer Now (147), 
working in partnership with Walk the Walk; Cancer Research UK 
(C30122/A11527; C30122/A15774); The European Academy of 
Allergy and Clinical Immunology; the Medical Research Council 
(MR/L023091/1); The Academy of Medical Sciences; CR UK/
NIHR in England/DoH for Scotland, Wales and Northern Ireland 
Experimental Cancer Medicine Centre (C10355/A15587), 
Austrian Science Fund (FWF) (P23398-B11; W1205-B09). JF-S 
is a recipient of an EAACI (European Academy of Allergy and 
Clinical Immunology) Exchange Research Fellowship 2016 and a 
Boehringer Ingelheim Fonds Travel Grant 2017. The research was 
supported by the National Institute for Health Research (NIHR) 
BRC based at Guy’s and St. Thomas’ NHS Foundation Trust 
and King’s College London (IS-BRC-1215-20006). The views 
expressed are those of the author(s) and not necessarily those of 
the NHS, the NIHR, or the Department of Health.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2017.01112/
full#supplementary-material.
reFerences
1. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, et  al. 
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances 
tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in 
breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res (2001) 
61:4892–900. 
2. Fu W, Wang Y, Zhang Y, Xiong L, Takeda H, Ding L, et al. Insights into HER2 
signaling from step-by-step optimization of anti-HER2 antibodies. MAbs 
(2014) 6:978–90. doi:10.4161/mabs.28786 
3. Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: 
pathophysiology, clinical use, and new advances in therapy. Chemother Res 
Pract (2012) 2012:743193. doi:10.1155/2012/743193 
4. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. 
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal anti-
body, inhibits basal and activated Her2 ectodomain cleavage in breast cancer 
cells. Cancer Res (2001) 61:4744–9. 
5. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, 
et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal 
cancer. N Engl J Med (2009) 360:1408–17. doi:10.1056/NEJMoa0805019 
6. Weiner GJ. Rituximab: mechanism of action. Semin Hematol (2010) 47:115–23. 
doi:10.1053/j.seminhematol.2010.01.011 
7. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic mel-
anoma. Clin Cancer Res (2011) 17:6958–62. doi:10.1158/1078-0432.ccr-11-1595 
8. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in 
cancer therapy. J Clin Oncol (2015) 33:1974–82. doi:10.1200/jco.2014.59.4358 
17
Ilieva et al. Functionally Active Fc Mutant Antibodies
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1112
9. Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, et al. 
Complement dependent cytotoxicity in chronic lymphocytic leukemia: 
ofatumumab enhances alemtuzumab complement dependent cytotoxicity 
and reveals cells resistant to activated complement. Leuk Lymphoma (2012) 
53:2218–27. doi:10.3109/10428194.2012.681657 
10. Tohyama Y, Yamamura H. Complement-mediated phagocytosis – the role of 
Syk. IUBMB Life (2006) 58:304–8. doi:10.1080/15216540600746377 
11. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, et al. Trastuzumab 
causes antibody-dependent cellular cytotoxicity-mediated growth inhibition 
of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug 
resistance. Mol Cancer Ther (2007) 6:2065–72. doi:10.1158/1535-7163.
mct-06-0766 
12. Miura D, Yoneyama K, Furuhata Y, Shimizu K. Paclitaxel enhances 
antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid 
recruitment of natural killer cells in HER2-positive breast cancer. J Nippon 
Med Sch (2014) 81:211–20. doi:10.1272/jnms.81.211 
13. Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, et al. Trastuzumab 
triggers phagocytic killing of high HER2 cancer cells in  vitro and in  vivo 
by interaction with Fcgamma receptors on macrophages. J Immunol (2015) 
194:4379–86. doi:10.4049/jimmunol.1402891 
14. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, 
resistance and future perspectives in HER2-overexpressing breast cancer. 
Ann Oncol (2007) 18:977–84. doi:10.1093/annonc/mdl475 
15. Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug 
delivery and therapy. Adv Drug Deliv Rev (2015) 91:109–24. doi:10.1016/j.
addr.2015.02.005 
16. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin 
Immunol (2007) 19:239–45. doi:10.1016/j.coi.2007.01.005 
17. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: 
successes, limitations and hopes for the future. Br J Pharmacol (2009) 
157:220–33. doi:10.1111/j.1476-5381.2009.00190.x 
18. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immu-
notherapy: a novel concept with promise for the treatment of cancer. MAbs 
(2014) 6:54–72. doi:10.4161/mabs.27029 
19. Beers SA, Glennie MJ, White AL. Influence of immunoglobulin isotype on 
therapeutic antibody function. Blood (2016) 127:1097–101. doi:10.1182/
blood-2015-09-625343 
20. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, 
et  al. Interaction with FcgammaRIIB is critical for the agonistic activity of 
anti-CD40 monoclonal antibody. J Immunol (2011) 187:1754–63. doi:10.4049/
jimmunol.1101135 
21. Park HI, Yoon HW, Jung ST. The highly evolvable antibody Fc domain. 
Trends Biotechnol (2016) 34:895–908. doi:10.1016/j.tibtech.2016.04.005 
22. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: 
focus on hypersensitivity responses. Oncoimmunology (2013) 2:e26333. 
doi:10.4161/onci.26333 
23. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, 
et al. Safety and immunotoxicity assessment of immunomodulatory mono-
clonal antibodies. MAbs (2010) 2:233–55. doi:10.4161/mabs.2.3.11782 
24. Crescioli S, Correa I, Karagiannis P, Davies AM, Sutton BJ, Nestle FO, et al. 
IgG4 characteristics and functions in cancer immunity. Curr Allergy Asthma 
Rep (2016) 16:7. doi:10.1007/s11882-015-0580-7 
25. Jacobsen FW, Stevenson R, Li C, Salimi-Moosavi H, Liu L, Wen J, et  al. 
Engineering an IgG scaffold lacking effector function with optimized devel-
opability. J Biol Chem (2017) 292:1865–75. doi:10.1074/jbc.M116.748525 
26. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis 
of human IgG-Fc glycoforms reveals a correlation between glycosylation 
and structural integrity. J Mol Biol (2003) 325:979–89. doi:10.1016/
S0022-2836(02)01250-0 
27. Roghanian A, Teige I, Martensson L, Cox KL, Kovacek M, Ljungars A, et al. 
Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor 
activity and overcome resistance to antibody therapy in  vivo. Cancer Cell 
(2015) 27:473–88. doi:10.1016/j.ccell.2015.03.005 
28. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. 
Aglycosylated immunoglobulin G1 variants productively engage activating 
Fc receptors. Proc Natl Acad Sci U S A (2008) 105:20167–72. doi:10.1073/
pnas.0809257105 
29. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. 
High-level expression of a recombinant antibody from myeloma cells using a 
glutamine synthetase gene as an amplifiable selectable marker. Nat Biotechnol 
(1992) 10:169–75. 
30. Maynard J, Georgiou G. Antibody engineering. Annu Rev Biomed Eng (2000) 
2:339–76. doi:10.1146/annurev.bioeng.2.1.339 
31. Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anticancer agents. 
Oncogene (2007) 26:3714–33. doi:10.1038/sj.onc.1210372 
32. Tanaka T, Yamada H, Kuroki M, Kodama S, Tamura K, Takamatsu Y. 
A modified adenovirus vector-mediated antibody screening method identi-
fies EphA2 as a cancer target. Transl Oncol (2017) 10:476–84. doi:10.1016/j.
tranon.2017.04.001 
33. Yu X, Wang L, Shen Y, Wang C, Zhang Y, Meng Y, et  al. Targeting EGFR/
HER2 heterodimerization with a novel anti-HER2 domain II/III antibody. 
Mol Immunol (2017) 87:300–7. doi:10.1016/j.molimm.2017.05.010 
34. Saeed AF, Wang R, Ling S, Wang S. Antibody engineering for pursuing a health-
ier future. Front Microbiol (2017) 8:473–88. doi:10.3389/fmicb.2017.00495 
35. Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell culture processes 
for monoclonal antibody production. MAbs (2010) 2:466–79. doi:10.4161/
mabs.2.5.12720 
36. Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, et al. 
A tool kit for rapid cloning and expression of recombinant antibodies. Sci Rep 
(2014) 4:5885. doi:10.1038/srep05885 
37. Klock HE, Koesema EJ, Knuth MW, Lesley SA. Combining the polymerase 
incomplete primer extension method for cloning and mutagenesis with 
microscreening to accelerate structural genomics efforts. Proteins (2008) 
71:982–94. doi:10.1002/prot.21786 
38. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagen-
esis by overlap extension using the polymerase chain reaction. Gene (1989) 
77:51–9. doi:10.1016/0378-1119(89)90358-2 
39. Reikofski J, Tao BY. Polymerase chain reaction (PCR) techniques for 
site-directed mutagenesis. Biotechnol Adv (1992) 10:535–47. doi:10.1016/ 
0734-9750(92)91451-J 
40. Unger T, Jacobovitch Y, Dantes A, Bernheim R, Peleg Y. Applications of the 
restriction free (RF) cloning procedure for molecular manipulations and pro-
tein expression. J Struct Biol (2010) 172:34–44. doi:10.1016/j.jsb.2010.06.016 
41. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, et  al. CSPG4 
protein as a new target for the antibody-based immunotherapy of triple- 
negative breast cancer. J Natl Cancer Inst (2010) 102:1496–512. doi:10.1093/
jnci/djq343 
42. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy 
requires constant antigen receptor occupancy and signaling. Nat Immunol 
(2005) 6:1160–7. doi:10.1038/ni1256 
43. Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, et  al. 
Multiple chimeric antigen receptors successfully target chondroitin sulfate 
proteoglycan 4 in several different cancer histologies and cancer stem cells. 
J Immunother Cancer (2014) 2:25. doi:10.1186/2051-1426-2-25 
44. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, et al. CSPG4, 
a potential therapeutic target, facilitates malignant progression of melanoma. 
Pigment Cell Melanoma Res (2011) 24:1148–57. doi:10.1111/j.1755-148X. 
2011.00929.x 
45. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, 
et al. Characterisation of an engineered trastuzumab IgE antibody and effector 
cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol 
Immunother (2009) 58:915–30. doi:10.1007/s00262-008-0607-1 
46. Neri D, Natali PG, Petrul H, Soldani P, Nicotra MR, Vola R, et al. Recombinant 
anti-human melanoma antibodies are versatile molecules. J Invest Dermatol 
(1996) 107:164–70. doi:10.1111/1523-1747.ep12329566 
47. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune 
responses. Nat Rev Immunol (2008) 8:34–47. doi:10.1038/nri2206 
48. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Trastuzumab – 
mechanism of action and use. N Engl J Med (2007) 357:1664; author reply 
1665–6. doi:10.1056/NEJMc072213 
49. O’Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et  al. 
Activated phosphoinositide 3-kinase/AKT signaling confers resistance 
to trastuzumab but not lapatinib. Mol Cancer Ther (2010) 9:1489–502. 
doi:10.1158/1535-7163.mct-09-1171 
50. Braren I, Greunke K, Pilette C, Mempel M, Grunwald T, Bredehorst R, et al. 
Quantitation of serum IgE by using chimeras of human IgE receptor and avian 
immunoglobulin domains. Anal Biochem (2011) 412:134–40. doi:10.1016/j.
ab.2010.12.013 
18
Ilieva et al. Functionally Active Fc Mutant Antibodies
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1112
51. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour 
growth inhibition by mitotic catastrophe in trastuzumab-resistant breast 
cancer cells in vivo. Breast Cancer Res (2011) 13:R46. doi:10.1186/bcr2868 
52. Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, et  al. 
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing 
IgG with FcalphaRI (CD89) binding. MAbs (2015) 7:743–51. doi:10.1080/ 
19420862.2015.1047570 
53. Zhang F, Zhang J, Liu M, Zhao L, LingHu R, Feng F, et al. Combating HER2-
overexpressing breast cancer through induction of calreticulin exposure by 
Tras-Permut CrossMab. Oncoimmunology (2015) 4:e994391. doi:10.4161/ 
2162402x.2014.994391 
54. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, 
Baracco EE, et  al. Classification of current anticancer immunotherapies. 
Oncotarget (2014) 5:12472–508. doi:10.18632/oncotarget.2998 
55. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. 
Cancer immun (2012) 12:14. 
56. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 
(2012) 12:14. doi:10.1038/nrc3236 
57. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison  CA III, Smith HO. 
Enzymatic assembly of DNA molecules up to several hundred kilobases. 
Nat Methods (2009) 6:343–5. doi:10.1038/nmeth.1318 
58. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered anti-
body Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 
(2006) 103:4005–10. doi:10.1073/pnas.0508123103 
59. Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G, et  al. 
Compensation of endogenous IgG mediated inhibition of antibody- 
dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. 
Mol Immunol (2007) 44:1815–7. doi:10.1016/j.molimm.2006.08.013 
60. Collins DM, O’Donovan N, McGowan PM, O’Sullivan F, Duffy MJ, 
Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotox-
icity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 
(2012) 23:1788–95. doi:10.1093/annonc/mdr484 
61. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu 
proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 
5:953–62. 
62. Niwa R, Satoh M. The current status and prospects of antibody engineering 
for therapeutic use: focus on glycoengineering technology. J Pharm Sci (2015) 
104:930–41. doi:10.1002/jps.24316 
63. Liu D, Tian Y, Sun D, Sun H, Jin Y, Dong M. The FCGR3A polymorphism pre-
dicts the response to rituximab-based therapy in patients with non-Hodgkin 
lymphoma: a meta-analysis. Ann Hematol (2016) 95:1483–90. doi:10.1007/
s00277-016-2723-x 
64. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical 
review of the role of Fc gamma receptor polymorphisms in the response to 
monoclonal antibodies in cancer. J Hematol Oncol (2013) 6:1. doi:10.1186/ 
1756-8722-6-1 
65. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. 
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy 
of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic 
breast cancer. J Clin Oncol (2008) 26:1789–96. doi:10.1200/jco.2007.14.8957 
66. Pandey JP, Namboodiri AM. Genetic variants of IgG1 antibodies and 
FcgammaRIIIa receptors influence the magnitude of antibody-dependent 
cell-mediated cytotoxicity against prostate cancer cells. Oncoimmunology 
(2014) 3:e27317. doi:10.4161/onci.27317 
67. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, 
et  al. FcgammaR2A and 3A polymorphisms predict clinical outcome of 
trastuzumab in both neoadjuvant and metastatic settings in patients with 
HER2-positive breast cancer. Ann Oncol (2011) 22:1302–7. doi:10.1093/
annonc/mdq585 
68. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization 
of antibody binding to FcgammaRIIa enhances macrophage phagocytosis 
of tumor cells. Mol Cancer Ther (2008) 7:2517–27. doi:10.1158/1535-7163.
mct-08-0201 
69. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for 
glyco-engineering. MAbs (2012) 4:419–25. doi:10.4161/mabs.20996 
70. Jean GW, Comeau JM. Role of obinutuzumab in the treatment of chronic lym-
phocytic leukemia. Am J Health Syst Pharm (2015) 72:933–42. doi:10.2146/
ajhp140282 
71. Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol 
Hematol (2001) 39:69–77. doi:10.1016/S1040-8428(01)00105-6 
72. Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, et al. 
Anti-folate receptor-alpha IgE but not IgG recruits macrophages to attack 
tumors via TNFalpha/MCP-1 signaling. Cancer Res (2017) 77:1127–41. 
doi:10.1158/0008-5472.can-16-1829 
73. Karagiannis SN, Josephs DH, Bax HJ, Spicer JF. Therapeutic IgE antibodies: 
harnessing a macrophage-mediated immune surveillance mechanism against 
cancer. Cancer Res (2017) 77:2779–83. doi:10.1158/0008-5472.can-17-0428 
74. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, et  al. 
Activity of human monocytes in IgE antibody-dependent surveillance and 
killing of ovarian tumor cells. Eur J Immunol (2003) 33:1030–40. doi:10.1002/
eji.200323185 
75. Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. 
In vivo imaging reveals a tumor-associated macrophage-mediated resistance 
pathway in anti-PD-1 therapy. Sci Transl Med (2017) 9:eaal3604. doi:10.1126/
scitranslmed.aal3604 
76. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 
subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 
(2013) 123:1457–74. doi:10.1172/jci65579 
Conflict of Interest Statement: SK and JS are founders and shareholders of IGEM 
Therapeutics Ltd. All other authors declare not conflicts of interest.
Copyright © 2017 Ilieva, Fazekas-Singer, Achkova, Dodev, Mele, Crescioli, Bax, 
Cheung, Karagiannis, Correa, Figini, Marlow, Josephs, Beavil, Maher, Spicer, Jensen-
Jarolim, Tutt and Karagiannis. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
